Islet transplant business moves forward with new financing and talent

336

The Neocrin Company is presently one of the leading biomedical companies involved in the research and development of a bio-artificial pancreas. This minimally invasive implantable device will be used for the treatment of insulin dependent diabetes.

Recently, Neocrin announced that it has raised $12.5 million in a self-managed private offering. The company sold approximately 2.5 million shares of stock to both existing and new investors.

In conjunction with the financing, Neocrin also announced that Dr. David W. Sharp, a world renowned islet transplant surgeon, has joined the company as executive vice president of research and medical affairs. While at Washington University, Sharp completed numerous successful human islet transplants.

“Without question, islet transplantation can be expected to demonstrate a dramatic improvement over conventional insulin therapy in helping prevent long-term complications of the disease,” claimed Sharp.

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.